Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Zepbound and Wegovy go head-to-head in weight loss trial
Posted
December 4, 2024
Views
1,919
Likes
25
Comments
9
Engagement
December 4, 2024
1,919
25
9
1.77%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
7:49Now PlayingEli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke about the results on "Bloomberg Open Interest."
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance
Visit for business news & analysis, uptotheminute market data, features, profiles and more.
Connect with Bloomberg Television on:
Connect with Bloomberg Business on:
More from Bloomberg:
Bloomberg Radio
Bloomberg Surveillance
Bloomberg Politics
Bloomberg Originals
Watch more on YouTube:
Bloomberg Technology
Bloomberg Originals
Bloomberg Quicktake
Bloomberg Espanol
Bloomberg Podcasts
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
